Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
News|Articles|October 15, 2018
MilliporeSigma Offers Insect Platform for Viral Vaccines and Gene Therapy Development
Author(s)Pharmaceutical Technology Editors
The company will collaborate with GlycoBac to offer an insect cell line for the development of viral vaccines and gene therapies.
Advertisement
On Oct. 10, 2018, MilliporeSigma is collaborating with GlycoBac, a Laramie, WY-based biotechnology company specializing in genetically engineered insect cells for manufacturing vaccines, diagnostics, or therapeutics, to offer a Sf-9 insect cell line.
According to the companies, GlycoBac’s development of a proven rhabdovirus-negative (RVN) cell line enables MilliporeSigma to offer the first Sf-9 platform that combined a rhabdovirus-free insect cell line with a corresponding, chemically defined cell culture medium. This will be the first non-mammalian cell line in MilliporeSigma’s cell culture portfolio, the company reports. The technology allows for access to a safer, high-performing vehicle for recombinant protein expression, virus-like particle vaccines, and adeno-associated-virus-based gene therapy production.
The insect cell line will provide time and cost savings in analytics and validation, and speed development by circumventing process steps normally required to prove elimination of rhabdovirus, according to the companies. In addition, MilliporeSigma’s chemically defined hydrolysate-free medium addresses consistency concerns while also reducing overall variability in growth and productivity.
MilliporeSigma’s insect cell line extends the company’s upstream offerings for viral-vaccine and gene-therapy applications and complements its mammalian CHOZN platform. The Sf-RVN platform will be available for purchase from a cGMP cell bank in 2019.
Source: MilliporeSigma
Advertisement
Related to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement